<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPL) are associated with <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological diseases</z:e> such as <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0002076'>migraine</z:hpo>, <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> and <z:hpo ids='HP_0000726'>dementia</z:hpo> and are thus associated with both vascular and non-vascular <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We have therefore examined the possibility that these antibodies interact directly with neuronal tissue by studying the electrophysiological effects of aPL on a brain synaptosoneurosome preparation </plain></SENT>
<SENT sid="2" pm="."><plain>IgG from patients with high levels of aPL and neurological involvement was purified by protein-G affinity chromatography as was control IgG pooled from ten sera with low levels of aPL </plain></SENT>
<SENT sid="3" pm="."><plain>Synaptoneurosomes were purified from perfused rat brain stem </plain></SENT>
<SENT sid="4" pm="."><plain>IgG from the patient with the highest level of aPL at a concentration equivalent to 1:5 serum dilution caused significant depolarization of the synaptoneurosomes as determined by accumulation of the lipophylic <z:chebi fb="36" ids="36916">cation</z:chebi> [3H]-<z:chebi fb="0" ids="44880">tetraphenylphosphonium</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>IgG from this patient as well as IgG from two elderly patients with high levels of aPL were subsequently shown to permeabilize the synaptosomes to labeled <z:chebi fb="0" ids="13389">nicotinamide adenine dinucleotide</z:chebi> (<z:chebi fb="0" ids="13389">NAD</z:chebi>) and <z:e sem="disease" ids="C0043167" disease_type="Disease or Syndrome" abbrv="">pertussis</z:e> toxin-<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi> transferase (PTX-A protein) as assayed by labeled <z:chebi fb="13" ids="16761">ADP</z:chebi>-ribosylation of G-proteins in the membranes </plain></SENT>
<SENT sid="6" pm="."><plain>No such effects were seen with the control IgG </plain></SENT>
<SENT sid="7" pm="."><plain>aPL may thus have the potential to disrupt neuronal function by direct action on nerve terminals </plain></SENT>
<SENT sid="8" pm="."><plain>These results may explain some of the non-thromboembolic <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> manifestations of the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>